Literature DB >> 24478612

Myelodysplastic syndrome versus idiopathic cytopenia of undetermined significance: the role of morphology in distinguishing between these entities.

Talyta Ellen de Jesus Dos Santos1, Romélia Pinheiro Gonçalves1, Fernando Barroso Duarte1.   

Abstract

Entities:  

Year:  2013        PMID: 24478612      PMCID: PMC3905828          DOI: 10.5581/1516-8484.20130069

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


× No keyword cloud information.
Myelodysplastic syndrome (MDS) is a heterogeneous group of diseases characterized by ineffective and dysplastic hematopoiesis and pancytopenia in the peripheral blood(. Minimal diagnostic criteria for MDS have been discussed by several working groups. The term idiopathic cytopenia of undetermined significance (ICUS) has been proposed to define patients who do not fill minimal criteria for MDS but present with persistent cytopenia not attributable to a hematological or non-hematological disease(. In medical services where immunohistochemistry, cytogenetics and studies of progenitor cell assays are still not available, the morphologic parameters may be the center of the diagnosis of ICUS. Several working groups have also discussed minimal morphological criteria for 'bone marrow dysplasia'. Based on these discussions, at least 10% of all cells in a given lineage should produce signs of dysplasia to fill this important criterion(. Patients with ICUS present mild dysplasia in one or more hematopoietic lineages. Figures 1 & 2 illustrate the myelogram of one patient with ICUS and one patient with MDS showing the levels of dysplasia in both settings. Distinguishing between these entities is important to understand the similarities and differences in pathologic mechanisms of the two hematologic diseases and so to direct the correct management of patients.
Figure

Figure 1A and 1B – Mild dyserythropoiesis (<10%) in patient with ICUS; presence of blabs. Figure 2A – Dyserythropoiesis (> 10%). Figure 2B – Dysmegakaryopoiesis; presence of blasts in patient with MDS (magnification: 1000x; HE stain)

Figure 1A and 1B – Mild dyserythropoiesis (<10%) in patient with ICUS; presence of blabs. Figure 2A – Dyserythropoiesis (> 10%). Figure 2B – Dysmegakaryopoiesis; presence of blasts in patient with MDS (magnification: 1000x; HE stain)
  3 in total

1.  Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.

Authors:  T Schroeder; L Ruf; A Bernhardt; B Hildebrandt; M Aivado; C Aul; N Gattermann; R Haas; U Germing
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

Review 2.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Authors:  Peter Valent; Hans-Peter Horny; John M Bennett; Christa Fonatsch; Ulrich Germing; Peter Greenberg; Torsten Haferlach; Detlef Haase; Hans-Jochen Kolb; Otto Krieger; Michael Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Michael Pfeilstöcker; Björn Rüter; Wolfgang R Sperr; Reinhard Stauder; Denise A Wells
Journal:  Leuk Res       Date:  2007-01-25       Impact factor: 3.156

Review 3.  Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.

Authors:  Peter Valent; Barbara J Bain; John M Bennett; Friedrich Wimazal; Wolfgang R Sperr; Ghulam Mufti; Hans-Peter Horny
Journal:  Leuk Res       Date:  2011-09-13       Impact factor: 3.156

  3 in total
  1 in total

1.  New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts.

Authors:  Lorena Bedotti Ribeiro; Erich V De Paula
Journal:  Rev Bras Hematol Hemoter       Date:  2016-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.